EUCTR2005-002544-25-FI进行中（未招募）不适用
A Multicentre, Multinational, Open-Label Trial (including Double-Blind, Placebo-Controlled Cross-Over Extension Part) to Evaluate the Time to Significant Pain Relief with Fentanyl TAIFUN® in the Treatment of Breakthrough Pain in Patients with Cancer on Maintenance Opioid Therapy for Persistent Pain. - FIND 2: Fentanyl Inhalation in Neoplastic Disease
AB Pharma Ltd0 个研究点目标入组 62 人开始时间: 2005年7月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Confirmed diagnosis of cancer
- •2.Age 18 years or more
- •3.Using a fixed dose of around-the-clock opioid or a combination of opioids for pain relief; either morphine 60-600mg/day, oxycodone 60-600 mg/day, methadone 15-200mg/day, transdermal fentanyl 25-300?g /hr or 12-120 mg/day hydromorphone, which has been stable for at least 5 days prior to the start of titration visit
- •4.Experiencing at least 1 episode of target breakthrough pain per day, which is responsive to short-acting opioid therapy
- •5.Written informed consent has been obtained
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Uncontrolled or rapidly increasing pain
- •2.Uncontrolled or rapidly increasing background pain
- •3.Intracranial tumours or cerebral metastases
- •5.Inadequate lung function, as defined by PEFR <60% of age-adjusted normal, or any other valid method judged by the investigator appropriate
- •6.Radiotherapy to the thorax within 30 days of the start of titration visit
- •7.Chemotherapy with a drug not used before in this patient within 30 days of the registration visit
- •8.Planned surgery during the study period
- •9.Known allergy or hypersensitivity to any of the drugs under investigation or their components
- •10.Any known contraindications to any of the drugs under investigation
- •11.Alcohol or drug abuse
- •12.Participation in any clinical study within 1 month of the start of titration visit, with the only exception of the study FIND (EUDRACT No. 2004-001620-21)
- •13.Cognitive impairment or any neurological or psychiatric disease which could compromise the ability of the subject to complete the assessments
- •14.Any clinical condition which, in the opinion of the investigator would not allow safe completion of the study or safe administration of the study drug (e.g. elderly or cachectic patient on the lowest dose of background opioidi therapy).
- •15.Pre-menopausal women (last menstruation ?1 year prior to the screening visit) who:
- •a.are not surgically sterile and/or
- •b.have a positive pregnancy test at the randomisation visit and/or
- •c.are of childbearing potential and are not practicing an acceptable means of birth control or do not plan to continue using this method throughout the study and/or
- •d.are nursing
研究者
相似试验
已完成
3 期
An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients with Prostate Cancer Requiring Androgen Deprivation Therapyprostate cancerNL-OMON38143Ferring25
进行中（未招募）
1 期
An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - FE200486 CS29Prostate CancerEUCTR2008-003931-19-FRFerring Pharmaceuticals A/S200
进行中（未招募）
1 期
An Open Multi-Centre Trial, Investigating a hormonel drug (Degarelix)given once a month followed by a period without treatment (calledintermittent androgen deprivation) in Patients with Prostate CancerRequiring Androgen Deprivation TherapyProstate CancerEUCTR2008-003931-19-BEFerring Pharmaceuticals A/S220
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - FE200486 CS29Prostate CancerEUCTR2008-003931-19-NLFerring Pharmaceuticals A/S200
进行中（未招募）
1 期
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2012-001711-23-LTovo Nordisk A/S60